compound 20j [PMID: 38564512]   Click here for help

GtoPdb Ligand ID: 13310

Synonyms: compound I-10 [WO2020233716A1] [1]
Compound class: Synthetic organic
Comment: This compound is a small molecule inhibitor of mitogen-activated protein kinase-interacting protein kinases (MNKs) 1 and 2 [2]. It was designed to treat malignancies with MNK/eukaryotic translation initiation factor 4E (eIF4E) axis defects; the MNKs being essential for eIF4E phosphorylation and regulation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 60.74
Molecular weight 505.61
XLogP 2.71
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCN(CC1)C2CCN(CC2)C(=O)C3=CC=C(C=C3)C4=NN5C(=CN=C5C=C4)C6=CC7=C(C=CC=C7)O6
Isomeric SMILES O=C(N1CCC(N2CCCCC2)CC1)C=3C=CC(=CC3)C=4C=CC=5N(N4)C(=CN5)C6=CC7=C(C=CC=C7)O6
InChI InChI=1S/C31H31N5O2/c37-31(35-18-14-25(15-19-35)34-16-4-1-5-17-34)23-10-8-22(9-11-23)26-12-13-30-32-21-27(36(30)33-26)29-20-24-6-2-3-7-28(24)38-29/h2-3,6-13,20-21,25H,1,4-5,14-19H2
InChI Key HDKZJMGFRSXWSJ-UHFFFAOYSA-N
References
1. Chen C, Zhang H, Yuan X, Zhou J, Hong J. (2020)
Imidazopyridazine mnk1/mnk2 kinase inhibitors, preparation method therefor and use thereof.
Patent number: WO2020233716A1. Assignee: Shanghai Daoen Biotechnology Co., Ltd., Shanghai Medici Biopharmaceutical Co., Ltd.. Priority date: 22/05/2020. Publication date: 26/11/2020.
2. Yuan X, Guan D, Chen C, Guo S, Wu H, Bu H, Yang CY, Wang M, Zhou J, Zhang H. (2024)
Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.
J Med Chem, 67 (7): 5437-5457. [PMID:38564512]